Janux doses first subject in Phase I prostate cancer therapy trial

Janux Therapeutics has announced the dosing of the first subject with its therapy, JANX007, in a Phase I clinical trial for prostate cancer.

The first-in-human trial of JANX007 will be carried out in metastatic castration-resistant prostate cancer (mCRPC) patients.